Published in Am J Med on August 01, 2004
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
Rate and predictors of treatment prescription for hepatitis C. Gut (2006) 2.31
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther (2013) 2.15
New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26
IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One (2012) 1.25
Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A (2009) 1.08
Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. Clin Mol Hepatol (2012) 0.93
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine (2014) 0.89
Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis (2011) 0.88
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc (2005) 0.87
High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clin Mol Hepatol (2013) 0.85
Demographics of a large cohort of urban chronic hepatitis C patients. Hepatol Int (2008) 0.85
Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int (2010) 0.82
Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study. J Clin Exp Hepatol (2012) 0.82
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. Clin Mol Hepatol (2012) 0.80
Molecular and contextual markers of hepatitis C virus and drug abuse. Mol Diagn Ther (2009) 0.80
Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79
Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin. Intervirology (2015) 0.79
Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. Gut Liver (2009) 0.79
Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes. Patient (2013) 0.79
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. Indian J Med Res (2013) 0.77
A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. Dig Dis Sci (2009) 0.76
Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore) (2017) 0.75
Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients. Clin Mol Hepatol (2013) 0.75
Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent. Genes Immun (2014) 0.75
Chronic Hepatitis C: Treatment, Complications, and Long-term Outcomes in a Population of Latino Veterans. P R Health Sci J (2016) 0.75
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol (2013) 1.68
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology (2013) 1.41
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology (2010) 1.35
Effects of Maryland's law banning "Saturday night special" handguns on homicides. Am J Epidemiol (2002) 1.22
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut (2011) 1.00
The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol (2005) 0.99
Low serum vitamin B12 levels in an outpatient HIV-infected population. Int J STD AIDS (2004) 0.98
The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis (2011) 0.98
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther (2013) 0.88
Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients. Antimicrob Agents Chemother (2012) 0.86
Cyclophilin inhibitors for hepatitis C therapy. Clin Liver Dis (2013) 0.84
Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti. BMC Gastroenterol (2004) 0.83
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. J Clin Gastroenterol (2014) 0.77
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. Clin Infect Dis (2014) 0.75
Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenet Genomics (2013) 0.75
Treatment of chronic hepatitis C in nonresponders to previous therapy. Curr Gastroenterol Rep (2003) 0.75
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. Liver Int (2014) 0.75